Last week, the FDA made its one pivotal trial policy official, sparking myriad questions from industry leaders, including around specific evidence required for the single study and why it hasn’t been ...
U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval ...
The Well News on MSN
FDA proposes new treatment approval pathway for ultra-rare diseases
WASHINGTON - The Food and Drug Administration on Monday introduced a regulatory pathway aimed at accelerating the development of drugs for ultra-rare diseases, providing new hope, in particular, to ...
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. When Sarepta Therapeutics revealed this month that a ...
FDA's accelerated pathway allows new drugs to enter the market based on interim measures rather than waiting for long-term results like overall survival. Pharmaceutical companies are required to run ...
Early access to new cancer drugs, granted accelerated approval by the U.S. Food and Drug Administration (FDA), has provided mixed benefits for patients while costing Medicare billions of dollars, ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL) executives outlined a strategy centered on advancing its WEE1 inhibitor azenosertib toward potential approval in platinum-resistant ovarian cancer (PROC), ...
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results